In a disclosure at the ASCO GI Cancers Symposium, BeiGene (NASDAQ:BGNE) announced that it is “converting” its Phase 3 clinical trial, BGB-290-303,
evaluating PARP inhibitor pamiparib (BGB-290) as maintenance therapy in
patients with inoperable locally advanced or metastatic gastric cancer
who have responded to first-line treatment with platinum-based chemo to
Phase 2.
The company said the change is not due to safety
or efficacy issues, but acknowledged that enrollment has been slower
than expected (120 subjects to date). It plans to evaluate a development
path after assessing the results from the study.
https://seekingalpha.com/news/3534486-beigene-downgrades-late-stage-study-of-parp-inhibitor-in-gastric-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.